XT
TSHA icon

XTX Topco’s Taysha Gene Therapies TSHA Stock Holding History

XTX Topco’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$689K Buy
101,195
+90,866
+880% +$538K 0.01% 2136
2026
Q1 		$46.2K Buy
+10,329
New +$48K ﹤0.01% 3343
2025
Q3 		– Sell
-320,737
Closed -$741K – 3296
2025
Q2 		$741K Buy
320,737
+117,608
+58% +$256K 0.03% 844
2025
Q1 		$282K Buy
+203,129
New +$340K 0.01% 1454
2024
Q2 		– Sell
-41,052
Closed -$118K – 2477
2024
Q1 		$118K Buy
41,052
+24,767
+152% +$51.6K 0.02% 1330
2023
Q4 		$28.8K Buy
+16,285
New +$32.5K 0.01% 1316
2023
Q2 		– Sell
-85,167
Closed -$67.9K – 1855
2023
Q1 		$67.9K Buy
+85,167
New +$110K 0.01% 1137

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

XTX Topco's TSHA Position: Q2 2026 in Review

XTX Topco increased its Taysha Gene Therapies (TSHA) stake by 880% in Q2 2026, buying an estimated $538K and bringing the position to 101,195 shares worth $689K. The position accounts for 0.01% of the portfolio, ranked #2136.

XTX Topco first reported a position in TSHA in Q1 2023 and has held it in 7 quarters since. The position peaked at $741K in Q2 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • XTX Topco held 101,195 shares of Taysha Gene Therapies worth $689K as of Q2 2026.
  • XTX Topco bought 90,866 Taysha Gene Therapies shares in Q2 2026, an estimated $538K.
  • Taysha Gene Therapies made up 0.01% of XTX Topco's portfolio in Q2 2026, its #2136 holding.
  • XTX Topco first reported a position in Taysha Gene Therapies in Q1 2023 and has held it in 7 quarters since.
  • XTX Topco's Taysha Gene Therapies position peaked at $741K in Q2 2025.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.